Art. -Nr.: HY-W008956

Myoseverin

Kundenbewertung

Based on 1 Customer Validation

Myoseverin is a microtubule-binding molecule and angiogenesis inhibitor. Myoseverin can induce the reversible fission of multinucleated myotubes into mononucleated fragments. In addition, Myoseverin exerts anti-angiogenic effects by inhibiting endothelial cell function and endothelial progenitor cell differentiation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.17%
CAS. Nr.: 267402-71-1
Formel: C₂₄H₂₈N₆O₂
Molecular Weight:432.52

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Myoseverin Chemical Structure

CAS. Nr.: 267402-71-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>10 μM Compound: Myoseverin	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 31610375]
CCRF-CEM	IC₅₀	5.7 μM Compound: myoseverin	Cytotoxicity against human CEM cells after 72 hrs by MTT assay Cytotoxicity against human CEM cells after 72 hrs by MTT assay	[PMID: 19349183]
HCT-116	IC₅₀	3.3 μM Compound: myoseverin	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 19349183]
HCT-116	IC₅₀	7.82 μM Compound: Myoseverin	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 31610375]
HepG2	IC₅₀	3.06 μM Compound: Myoseverin	Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 31610375]
MCF7	IC₅₀	11.5 μM Compound: myoseverin	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 19349183]
MES-SA	IC₅₀	8.5 μM Compound: myoseverin	Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay Cytotoxicity against human MES-SA cells after 72 hrs by MTT assay	[PMID: 19349183]
SW48	IC₅₀	2.7 μM Compound: myoseverin	Cytotoxicity against human SW48 cells after 72 hrs by MTT assay Cytotoxicity against human SW48 cells after 72 hrs by MTT assay	[PMID: 19349183]
SW480	IC₅₀	4.8 μM Compound: myoseverin	Cytotoxicity against human SW480 cells after 72 hrs by MTT assay Cytotoxicity against human SW480 cells after 72 hrs by MTT assay	[PMID: 19349183]
U-937	GI₅₀	4 μM Compound: Myoseverin	Growth inhibition of human U937 cells Growth inhibition of human U937 cells	[PMID: 11741468]

In Vitro

Myoseverin (20 μM; 24 h) promotes the fission of multinucleated myotubes into mononucleated fragments with "bead-on-a-string" constriction morphology, and causes disassembly of the microtubule cytoskeleton with microtubules aggregating around the nucleus and fragmenting in mouse C2C12 myotubes^[1].
Myoseverin (20 μM; 24 h) promotes DNA synthesis and colony formation, and regulates the expression of more than 93 genes, involving extracellular matrix remodeling, growth factors, immunomodulatory pathways, etc in mouse C2C12 myotubes^[1].
Myoseverin (0-80 μM; 1-7 d) inhibits cell proliferation (IC₅₀: 8 μM) in a reversible manner and suppresses cell migration in human umbilical vein endothelial cells^[2].
Myoseverin (0-80 μM; 7 d) reduces the differentiation of endothelial progenitor cells into adherent cells in human cord blood mononuclear cells^[2].
Myoseverin (0-20 μM; 7 d) inhibits the acetylated low-density lipoprotein (ac-LDL) uptake ability and the expression of endothelial markers (KDR, CD31, vWF) in endothelial progenitor cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

Human umbilical vein endothelial cells
Concentration:

0, 2.5, 5, 10, 20, 40 and 80 μM
Incubation Time:

72 h
Result:

Inhibited the cell viability.

In Vivo

Myoseverin (0-10 μg; topical application; single dose) inhibits in vivo angiogenesis in the chick chorioallantoic membrane model^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

4.5-day-old chick embryos (chorioallantoic membrane (CAM) model was established by normal incubation of eggs)^[2]
Dosage:

0, 0.1, 1, 5 and 10 μg/embryo
Administration:

Topical application; single dose (48 h)
Result:

Did not show significant inhibition at low doses (0.1 μg or 1 μg/embryo).
Potently inhibited in vivo angiogenesis by showing a marked inhibition zone around the implanted cover slip without affecting embryo’s viability at 5 μg or 10 μg/embryo.

Chemical Information

CAS. Nr. 267402-71-1
Appearance Solid
Molecular Weight 432.52
Formel C₂₄H₂₈N₆O₂
Color Off-white to light yellow
SMILES

CC(N1C=NC2=C(NCC3=CC=C(OC)C=C3)N=C(NCC4=CC=C(OC)C=C4)N=C12)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (578.01 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3120 mL

11.5602 mL

23.1203 mL

5 mM

0.4624 mL

2.3120 mL

4.6241 mL

10 mM

0.2312 mL

1.1560 mL

2.3120 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.81 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (4.81 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Rosania GR, et al. Myoseverin, a microtubule-binding molecule with novel cellular effects. Nat Biotechnol. 2000;18(3):304-308. [Content Brief]

[2]. Park HE, et al. Myoseverin is a potential angiogenesis inhibitor by inhibiting endothelial cell function and endothelial progenitor cell differentiation. DNA Cell Biol. 2006 Sep;25(9):514-22. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3120 mL	11.5602 mL	23.1203 mL	57.8008 mL
	5 mM	0.4624 mL	2.3120 mL	4.6241 mL	11.5602 mL
	10 mM	0.2312 mL	1.1560 mL	2.3120 mL	5.7801 mL
	15 mM	0.1541 mL	0.7707 mL	1.5414 mL	3.8534 mL
	20 mM	0.1156 mL	0.5780 mL	1.1560 mL	2.8900 mL
	25 mM	0.0925 mL	0.4624 mL	0.9248 mL	2.3120 mL
	30 mM	0.0771 mL	0.3853 mL	0.7707 mL	1.9267 mL
	40 mM	0.0578 mL	0.2890 mL	0.5780 mL	1.4450 mL
	50 mM	0.0462 mL	0.2312 mL	0.4624 mL	1.1560 mL
	60 mM	0.0385 mL	0.1927 mL	0.3853 mL	0.9633 mL
	80 mM	0.0289 mL	0.1445 mL	0.2890 mL	0.7225 mL
	100 mM	0.0231 mL	0.1156 mL	0.2312 mL	0.5780 mL

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Myoseverin

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Anti-Aging Compound Library

Anti-Cardiovascular Disease Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Anti-Obesity Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Myoseverin

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Anti-Aging Compound Library

Anti-Cardiovascular Disease Compound Library

Cytoskeleton Compound Library

Anti-Lung Cancer Compound Library

Anti-Obesity Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Myoseverin Related Classifications

HY-W008956 Related Classifications